Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysis

Vascular Pharmacology

Volumn 65, Issue , 2015, Pages 23-30

  Choi, Hye Duck ^a   Shin, Wan Gyoon ^b   Lee, Ju Yeun ^c   Kang, Byoung Cheol ^b  

^a Yeungnam University   (South Korea)

^b Seoul National University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Adverse events; Dyslipidemia; Fibrates; Lipid profiles; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; CREATINE KINASE; CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MUSCLE DISEASE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DRUG COMBINATION; DYSLIPIDEMIAS;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84924495415     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.11.002     Document Type: Article

References (29)

1. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
2. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
3. Beukhof C., Van De Oever C., Cabezas M.C., Schrama Y. Fibrate induced renal insufficiency. Eur J Intern Med 2011, 22(Suppl. 1):s11-s12.
4. Brown W.V. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am J Cardiol 2007, 99:19C-21C.
5. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
6. 2 mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med 2012, 23:633-638.
7. Davidson M.H., Armani A., McKenney J.M., Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 2007, 99:3C-18C.
8. DerSimonian R., Larid N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
9. Durrington P.N., Tuomilehto J., Hamann A., Kallend D., Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004, 64:137-151.
10. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
11. Enger C., Gately R., Ming E.E., Niemcryk S.J., Williams L., McAfee A.T. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010, 106:1594-1601.
12. Farnier M., Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol 2000, 85:53-57. the French Fluvastatin Study Group.
13. Filippatos T.D. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther 2010, 26:245-255.
14. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
15. Goldberg A.C., Bittner V., Pepine C.J. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol 2011, 107:898-905.
16. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
17. Jones P.H., Cusi K., Davidson M.H., Kelly M.T., Setze C.M., Thakker K., et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010, 10:73-84.
18. Jun M., Zhu B., Tonelli M., Jardine M.J., Patel A., Neal B., et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2012, 60:2061-2071.
19. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005, 366:1849-1861.
20. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
21. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective sties of diseases. J Natl Cancer Inst 1959, 22:719-748.
22. Marais G.E., Larson K.K. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990, 112:228-230.
23. McKenney J.M. Introduction. Report of the National Lipid Association's Safety Task Force: the nonstatins. Am J Cardiol 2007, 99:1C-58C.
24. Mohiuddin S.M., Pepine C.J., Kelly M.T., Buttler S.M., Setze C.M., Sleep D.J., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009, 157:195-203.
25. Pauciullo P., Borgnino C., Paoletti R., Mariani M., Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000, 150:429-436.
26. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
27. Roth E.M., Rosenson R.S., Carlson D.M., Fukumoto S.M., Setze C.M., Blasetto J.W., et al. Efficacy and safety of rosuvastatin 5mg in combination with fenofibric acid 135mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther 2010, 24:421-428.
28. Vega G.L., Ma P.T., Cater N.B., Filipchuk N., Meguro S., Garcia-Garcia A.B., et al. Effects of adding fenofibrate (200mg/day) to simvastatin (10mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2002, 91:956-960.
29. Winklund O., Angeline B., Bergman M., Berglund L., Bondjers G., Carlsson A., et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993, 94:13-20.